Andres McAllister
Chief Tech/Sci/R&D Officer chez BIOINVENT INTERNATIONAL AB
Fortune : 4 784 $ au 31/03/2024
Profil
Andres McAllister is currently the Chief Medical Officer at BioInvent International AB since 2017.
Prior to this, he worked as the Chief Scientific Officer at Debiopharm International SA from 2004 to 2015.
He also held positions as Director-Research & Development at Immune Design Corp., Non-Executive Director at Immunexpress Pty Ltd., and Principal at Institut Pasteur, The University of California, San Francisco, and Centre d'Immunologie Pierre Fabre.
Dr. McAllister holds a doctorate degree from Université Paris 1 Panthéon-Sorbonne and Universidad del Rosario.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/12/2022 | 3 009 ( 0,00% ) | 4 784 $ | 31/03/2024 |
Postes actifs de Andres McAllister
| Sociétés | Poste | Début |
|---|---|---|
| BIOINVENT INTERNATIONAL AB | Chief Tech/Sci/R&D Officer | 01/01/2017 |
Anciens postes connus de Andres McAllister
| Sociétés | Poste | Fin |
|---|---|---|
Debiopharm International SA
 Debiopharm International SA Pharmaceuticals: MajorHealth Technology Debiopharm International SA operates as a biopharmaceutical development company with focus on biologics and drug evaluation, licensing and development. It formulates and develops products for the treatment of cancer, endometriosis, uterine fibroids and hepatitis. The company was founded in 1979 and is headquartered in Lausanne, Switzerland. | Chief Tech/Sci/R&D Officer | 01/09/2015 |
Immunexpress Pty Ltd.
 Immunexpress Pty Ltd. Medical SpecialtiesHealth Technology Immunexpress Pty Ltd. engages in creating molecular diagnostics for sepsis. The company was founded by Roslyn Brandon, Mervyn Rees Thomas and Richard Bruce Brandon and in 2006 and is headquartered in Toowong, Australia. | Director/Board Member | - |
| Centre d'Immunologie Pierre Fabre | Corporate Officer/Principal | - |
Institut Pasteur
 Institut Pasteur Investment Trusts/Mutual FundsMiscellaneous The Institut Pasteur is a private non-profit foundation which contributes to the prevention and treatment of disease, through research, education, and public health activities. The firm was founded in 1887, and is based in Paris. | Corporate Officer/Principal | - |
| The University of California, San Francisco | Corporate Officer/Principal | - |
Formation de Andres McAllister
| Université Paris 1 Panthéon-Sorbonne | Doctorate Degree |
| Universidad del Rosario | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BIOINVENT INTERNATIONAL AB | Health Technology |
| Entreprise privées | 5 |
|---|---|
Institut Pasteur
Institut Pasteur Investment Trusts/Mutual FundsMiscellaneous The Institut Pasteur is a private non-profit foundation which contributes to the prevention and treatment of disease, through research, education, and public health activities. The firm was founded in 1887, and is based in Paris. | Miscellaneous |
Debiopharm International SA
Debiopharm International SA Pharmaceuticals: MajorHealth Technology Debiopharm International SA operates as a biopharmaceutical development company with focus on biologics and drug evaluation, licensing and development. It formulates and develops products for the treatment of cancer, endometriosis, uterine fibroids and hepatitis. The company was founded in 1979 and is headquartered in Lausanne, Switzerland. | Health Technology |
Immune Design Corp.
 Immune Design Corp. Pharmaceuticals: MajorHealth Technology Immune Design Corp. is a clinical-stage immunotherapy company focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. It develops multiple product candidates from its discovery platforms, ZVex and GLAAS. The company was founded by Steven G. Reed and David Baltimore on February 20, 2008 and is headquartered in Kenilworth, NJ. | Health Technology |
Immunexpress Pty Ltd.
Immunexpress Pty Ltd. Medical SpecialtiesHealth Technology Immunexpress Pty Ltd. engages in creating molecular diagnostics for sepsis. The company was founded by Roslyn Brandon, Mervyn Rees Thomas and Richard Bruce Brandon and in 2006 and is headquartered in Toowong, Australia. | Health Technology |
| Centre d'Immunologie Pierre Fabre |
